Attached files

file filename
EX-99 - EX-99.7 - PLUS THERAPEUTICS, INC.cytx-ex997_38.htm
EX-99 - EX-99.6 - PLUS THERAPEUTICS, INC.cytx-ex996_25.htm
EX-99 - EX-99.5 - PLUS THERAPEUTICS, INC.cytx-ex995_26.htm
EX-99 - EX-99.4 - PLUS THERAPEUTICS, INC.cytx-ex994_27.htm
EX-99 - EX-99.3 - PLUS THERAPEUTICS, INC.cytx-ex993_28.htm
EX-99 - EX-99.2 - PLUS THERAPEUTICS, INC.cytx-ex992_29.htm
EX-99 - EX-99.1 - PLUS THERAPEUTICS, INC.cytx-ex991_30.htm
EX-8 - EX-8.1 - PLUS THERAPEUTICS, INC.cytx-ex81_31.htm
EX-5 - EX-5.1 - PLUS THERAPEUTICS, INC.cytx-ex51_32.htm
EX-4 - EX-4.36 - PLUS THERAPEUTICS, INC.cytx-ex436_33.htm
EX-4 - EX-4.35 - PLUS THERAPEUTICS, INC.cytx-ex435_34.htm
EX-4 - EX-4.28 - PLUS THERAPEUTICS, INC.cytx-ex428_35.htm
EX-3 - EX-3.8 - PLUS THERAPEUTICS, INC.cytx-ex38_36.htm
EX-1 - EX-1.1 - PLUS THERAPEUTICS, INC.cytx-ex11_211.htm
S-1/A - FORM S-1/A - PLUS THERAPEUTICS, INC.cytx-s1a_20180605.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Cytori Therapeutics, Inc.

San Diego, California

We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 9, 2018, relating to the consolidated financial statements and schedule of Cytori Therapeutics, Inc. (“Company”), which is incorporated by reference in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

We also consent to the reference to us under the caption “Experts” in the Prospectus.

/s/ BDO USA, LLP

San Diego, California

June 6, 2018